The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have recurrent platinum-sensitive ovarian, fallopian tube or peritoneal cancer, defined as cancer that has not returned within six months of platinum-containing chemotherapy. The purpose of this study is to find out if combined therapy with an immune therapy drug (tremelimumab) and a PARP inhibitor drug (olaparib) is better or worse than treatment with olaparib alone for your recurrent ovarian, fallopian tube or peritoneal cancer. You will either receive both tremelimumab and olaparib or you will get olaparib alone.
Your participation will continue as long as the treatment is helping you. Treatment with olaparib will continue until you or your doctor decide it is no longer good for you to do so. The treatment with tremelimumab will stop after 2 years. There will also be a follow up period lasting 5 years.
Study-related procedures that are being done beyond your standard of care will be provided at no
cost to your or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04034927